Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update
| Autor: | Ying-Shan Han, Thibault Mesplède |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.drug_class Bioinformatics Antiviral Agents Virus Zika virus 03 medical and health sciences In vivo medicine Animals Humans Pharmacology (medical) Repurposing Pharmacology biology Zika Virus Infection business.industry Drug Repositioning Viral Vaccines Drugs Investigational Zika Virus General Medicine biology.organism_classification Clinical trial Drug repositioning Flavivirus 030104 developmental biology Drug Design Antiviral drug business |
| Zdroj: | Expert Opinion on Investigational Drugs. 27:951-962 |
| ISSN: | 1744-7658 1354-3784 |
| DOI: | 10.1080/13543784.2018.1548609 |
| Popis: | The Zika virus (ZIKV) infection results in severe neurological complications and has emerged as a threat to public health worldwide. No drugs or vaccines are available for use in the clinic and the need for novel and effective therapeutic agents is urgent.This review describes the latest progress of antiviral development for the treatment of ZIKV infection; it primarily focuses on the literature describing 20 potential anti-ZIKV drugs/agents currently being tested in vivo or in clinical trials. The paper also discusses the need for novel ZIKV inhibitors and the critical issues for successful antiviral drug development.So far, 20 compounds have been tested in vivo and three in the clinical trials; progressing these compounds to the clinic is a challenge. Novel ZIKV inhibitors that target virus or host factors are urgently needed. Knowledge-driven drug repurposing, structure-based discovery, RNA interference, long noncoding RNAs, miRNAs, and peptide inhibitors may pave the way for the discovery of such novel agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|